Northwest Biotherapeutics (NWBO) Change in Accured Expenses (2010 - 2026)

Northwest Biotherapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $886000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 79.75% year-over-year to $886000.0; the TTM figure through Mar 2026 stood at $4.3 million (down 51.45% YoY), while the FY2025 annual figure was $7.8 million, down 13.26% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $886000.0, up from -$1.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.5 million in Q1 2024, with the low at -$2.6 million in Q4 2023.
• The 5-year median for Change in Accured Expenses is $886000.0 (2026), against an average of $1.2 million.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses surged 640.58% in 2024, then plunged 374.38% in 2025.
• Northwest Biotherapeutics' Change in Accured Expenses stood at $2.2 million in 2022, then tumbled by 216.33% to -$2.6 million in 2023, then soared by 115.42% to $402000.0 in 2024, then slumped by 374.38% to -$1.1 million in 2025, then jumped by 180.33% to $886000.0 in 2026.
• Business Quant data shows NWBO's Change in Accured Expenses at $886000.0 in Q1 2026, -$1.1 million in Q4 2025, and $1.3 million in Q3 2025.